{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:41:13Z","timestamp":1790538073202,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T00:00:00Z","timestamp":1480464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1038\/ja.2016.137","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T07:21:22Z","timestamp":1480490482000},"page":"527-533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Nature nurtures the design of new semi-synthetic macrolide antibiotics"],"prefix":"10.1038","volume":"70","author":[{"given":"Prabhavathi","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,30]]},"reference":[{"key":"BFja2016137_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/antibiotics5030029","volume":"5","author":"D Jelic","year":"2016","unstructured":"Jelic, D. & Antolovic, R. From erythromycin to azithromycin and new potential ribosome-binding antimicrobials. Antibiotics (Basel) 5, 29 (2016).","journal-title":"Antibiotics (Basel)"},{"key":"BFja2016137_CR2","volume-title":"Macrolide Antibiotics: Chemistry Biology, and Practice","author":"S Omura","year":"2002","unstructured":"Omura, S. Macrolide Antibiotics: Chemistry Biology, and Practice, 2nd edn (Academic Press, 2002)."},{"key":"BFja2016137_CR3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1155\/2015\/934594","volume":"26","author":"GG Zhanel","year":"2015","unstructured":"Zhanel, G. G., Walkty, A. J. & Karlowsky, J. A. Fidaxomicin: a novel agent for the treatment of Clostridium difficile infection. Can. J. Infect. Dis. Med. Microbiol 26, 305\u2013312 (2015).","journal-title":"Can. J. Infect. Dis. Med. Microbiol"},{"key":"BFja2016137_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1124\/jpet.112.200733","volume":"345","author":"Y Kobayashi","year":"2013","unstructured":"Kobayashi, Y. et al. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-\u03baB inhibition. J. Pharmacol. Exp. Ther. 345, 76\u201384 (2013).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFja2016137_CR5","first-page":"281","volume":"2","author":"J McGuire","year":"1952","unstructured":"McGuire, J. et al. Ilotycin, a new antibiotic. Antibiot. Chemother. 2, 281\u2013283 (1952).","journal-title":"Antibiot. Chemother."},{"key":"BFja2016137_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1021\/cr030107f","volume":"105","author":"L Katz","year":"2005","unstructured":"Katz, L. & Ashley, G. W. Translation and protein synthesis: macrolides. Chem. Rev. 105, 499\u2013528 (2005).","journal-title":"Chem. Rev."},{"key":"BFja2016137_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ijantimicag.2007.10.022","volume":"31","author":"DJ Farrell","year":"2008","unstructured":"Farrell, D. J., Couturier, C. & Hryniewicz, W. Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003-2004). Int. J. Antimicrob. Agents 31, 245\u2013249 (2008).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"BFja2016137_CR8","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1128\/AAC.05658-11","volume":"56","author":"SH Kim","year":"2012","unstructured":"Kim, S. H. et al. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Antimicrob. Agents Chemother. 56, 1418\u20131426 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2016137_CR9","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1517\/13543784.8.8.1171","volume":"8","author":"A Bryskier","year":"1999","unstructured":"Bryskier, A. New research in macrolides and ketolides since 1997. Expert Opin. Investig. Drugs 8, 1171\u20131194 (1999).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"BFja2016137_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1128\/AAC.33.1.78","volume":"33","author":"PB Fernandes","year":"1989","unstructured":"Fernandes, P. B., Baker, W. R., Freiberg, L. A., Hardy, D. J. & McDonald, E. J. New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance. Antimicrob. Agents Chemother. 33, 78\u201381 (1989).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2016137_CR11","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1021\/jm00280a003","volume":"15","author":"S Omura","year":"1972","unstructured":"Omura, S. & Tishler, M. Relationship of structures and microbiological activities of the 16-membered macrolides. J. Med. Chem. 15, 1011\u20131015 (1972).","journal-title":"J. Med. Chem."},{"issue":"21","key":"BFja2016137_CR12","doi-asserted-by":"publisher","first-page":"12111","DOI":"10.1073\/pnas.95.21.12111","volume":"95","author":"Y Xue","year":"1998","unstructured":"Xue, Y., Zhao, L., Liu, H. W. & Sherman, D. H. A gene cluster for macrolide antibiotic biosynthesis in Streptomyces venezuelae: architecture of metabolic diversity. Proc. Natl Acad. Sci. USA 95 (21), 12111\u201312116 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFja2016137_CR13","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2165\/00003088-200544090-00003","volume":"44","author":"J Shi","year":"2005","unstructured":"Shi, J., Montay, G. & Bhargava, V. O. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin. Pharmacokinet. 44, 915\u2013934 (2005).","journal-title":"Clin. Pharmacokinet."},{"key":"BFja2016137_CR14","doi-asserted-by":"publisher","first-page":"961","DOI":"10.2174\/1568026033452140","volume":"3","author":"T Asaka","year":"2003","unstructured":"Asaka, T., Manaka, A. & Sugiyama, H. Recent developments in macrolide antimicrobial research. Curr. Top. Med. Chem. 3, 961\u2013989 (2003).","journal-title":"Curr. Top. Med. Chem."},{"key":"BFja2016137_CR15","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1128\/JB.185.14.4276-4279.2003","volume":"185","author":"R Berisio","year":"2003","unstructured":"Berisio, R. et al. Structural insight into the antibiotic action of telithromycin against resistant mutants. J. Bacteriol. 185, 4276\u20134279 (2003).","journal-title":"J. Bacteriol."},{"key":"BFja2016137_CR16","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1056\/NEJMp078032","volume":"356","author":"DB Ross","year":"2007","unstructured":"Ross, D. B. The FDA and the case of Ketek. N. Engl. J. Med. 356, 1601\u20131604 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFja2016137_CR17","unstructured":"FDA. Briefing Document for Telithromycin (Ketek), Joint Meeting of the Anti-Infective Drug Advisory Committee, Drug Safety and Risk Management Advisory Committee. \n                    http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/briefing\/2006-4266b1-02-01-FDA-DAIOP.pdf\n                    \n                   (2006)."},{"key":"BFja2016137_CR18","unstructured":"FDA. Telithromycin (marketed as Ketek) Information \n                    http:\/\/www.fda.gov\/drugs\/drugsafety\/postmarketdrugsafetyinformationforpatientsandproviders\/ucm107824.htm\n                    \n                   (2007)."},{"key":"BFja2016137_CR19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1517\/13543784.17.3.387","volume":"17","author":"MR Hammerschlag","year":"2008","unstructured":"Hammerschlag, M. R. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections. Expert Opin. Investig. Drugs 17, 387\u2013400 (2008).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"BFja2016137_CR20","unstructured":"FDA. Cethromycin Briefing Document for the Anti-Infective Drugs Advisory Committee. \n                    http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM161850.pdf\n                    \n                   (2009)."},{"key":"BFja2016137_CR21","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1128\/AAC.01469-10","volume":"55","author":"T Sato","year":"2011","unstructured":"Sato, T. et al. In vitro antibacterial activity of modithromycin, a novel 6,11-bridged bicyclolide, against respiratory pathogens, including macrolide-resistant Gram-positive cocci. Antimicrob. Agents Chemother. 55, 1588\u20131593 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2016137_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.21775\/9781908230546.20","volume-title":"Antibiotics: Current Innovations and Future Trends","author":"P Fernandes","year":"2015","unstructured":"Fernandes, P., Sanchez, S. & Demain, A.L . Antibiotics: Current Innovations and Future Trends 375\u2013393 Caister Academic Press, Norfolk, UK, 2015)."},{"key":"BFja2016137_CR23","unstructured":"Pereira, D., Li, J., Fernandes, P. & Matsa, S. Pikromycin derivative of solithromycin: discussion of activity. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy No. F1505 (San Francisco, CA, (2012)."},{"key":"BFja2016137_CR24","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1128\/AAC.00840-10","volume":"54","author":"D Bertrand","year":"2010","unstructured":"Bertrand, D., Bertrand, S., Neveu, E. & Fernandes, P. Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors. Antimicrob. Agents Chemother. 54, 5399\u20135402 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2016137_CR25","first-page":"30642","volume":"pii: S0968-0896","author":"P Fernandes","year":"2016","unstructured":"Fernandes, P., Martens, E., Bertrand, D. & Pereira, D. The solithromycin journey-It is all in the chemistry. Bioorg. Med. Chem pii: S0968-0896, 30642\u201330643 (2016).","journal-title":"Bioorg. Med. Chem"},{"key":"BFja2016137_CR26","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1128\/AAC.00860-10","volume":"54","author":"B Llano-Sotelo","year":"2010","unstructured":"Llano-Sotelo, B. et al. Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis. Antimicrob. Agents Chemother. 54, 4961\u20134970 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2016137_CR27","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1358\/dof.2011.036.10.1622079","volume":"36","author":"P Fernandes","year":"2011","unstructured":"Fernandes, P., Pereira, D., Jamieson, B. & Keedy, K. Solithromycin. Macrolide antibiotic. Drugs Future 36, 751\u2013758 (2011).","journal-title":"Drugs Future"},{"key":"BFja2016137_CR28","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1128\/AAC.01429-10","volume":"55","author":"JG Still","year":"2011","unstructured":"Still, J. G. et al. Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects. Antimicrob. Agents Chemother. 55, 1997\u20132003 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2016137_CR29","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1128\/AAC.02561-15","volume":"60","author":"D Gonzalez","year":"2016","unstructured":"Gonzalez, D. et al. Solithromycin pharmacokinetics in plasma and dried blood spots and safety in adolescents. Antimicrob. Agents Chemother. 60, 2572\u20132576 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2016137_CR30","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1473-3099(16)00017-7","volume":"16","author":"CM Barrera","year":"2016","unstructured":"Barrera, C. M. et al. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL). Lancet Infect. Dis. 16, 421\u2013430 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"BFja2016137_CR31","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1093\/cid\/ciw490","volume":"63","author":"TM File Jr.","year":"2016","unstructured":"File, T. M. Jr. et al. SOLITAIRE-IV: A randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia. Clin. Infect. Dis. 63, 1007\u20131016 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"BFja2016137_CR32","unstructured":"Pereira, D., Patel, M. & Deo, K. (Cempra, Inc.). Process for the preparation of macrolide antibacterial agents WO2009055557 (2009)."},{"key":"BFja2016137_CR33","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1021\/jo00245a038","volume":"53","author":"WR Baker","year":"1988","unstructured":"Baker, W. R., Clark, J. D., Stephens, R. L. & Kim, K. H. Modification of macrolide antibiotics. Synthesis of 11-deoxy-11-(carboxyamino)-6-O-methylerythromycin A 11,12-(cyclic esters) via an intramolecular Michael reaction of O-carbamates with an alpha, beta-unsaturated ketone. J. Org. Chem. 53, 2340\u20132345 (1988).","journal-title":"J. Org. Chem."},{"key":"BFja2016137_CR34","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1021\/op300064b","volume":"16","author":"B Li","year":"2012","unstructured":"Li, B. et al. Process development of a novel azetidinyl ketolide antibiotic. Org. Process Res. Dev. 16, 788\u2013797 (2012).","journal-title":"Org. Process Res. Dev."},{"key":"BFja2016137_CR35","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.2174\/0929867013371671","volume":"8","author":"YJ Wu","year":"2001","unstructured":"Wu, Y. J. & Su, W. G. Recent developments on ketolides and macrolides. Curr. Med. Chem. 8, 1727\u20131758 (2001).","journal-title":"Curr. Med. Chem."},{"key":"BFja2016137_CR36","unstructured":"Hwang, C. et al. SAR of 11,12-carbamate macrolides\/ketolides linked with 1,4-substituted [1,2,3]-triazoles. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy \/Infectious Diseases Society of America 46th Annual Meeting, No. F1-3973 (Washington, DC, USA, (2008)."},{"key":"BFja2016137_CR37","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1021\/jo011148j","volume":"67","author":"CW Tornoe","year":"2002","unstructured":"Tornoe, C. W., Christensen, C. & Meldal, M. Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J. Org. Chem. 67, 3057\u20133064 (2002).","journal-title":"J. Org. Chem."},{"key":"BFja2016137_CR38","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1002\/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4","volume":"41","author":"VV Rostovtsev","year":"2002","unstructured":"Rostovtsev, V. V., Green, L. G., Fokin, V. V. & Sharpless, K. B. A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective \"ligation\" of azides and terminal alkynes. Angew. Chem. Int. Ed. Engl. 41, 2596\u20132599 (2002).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"BFja2016137_CR39","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nature17967","volume":"533","author":"IB Seiple","year":"2016","unstructured":"Seiple, I. B. et al. A platform for the discovery of new macrolide antibiotics. Nature 533, 338\u2013345 (2016).","journal-title":"Nature"},{"key":"BFja2016137_CR40","unstructured":"Satav, J., Takalkar, S., Kulkarni, A., Bhagwat, S. & Patel, M. WCK 4873 (Nafithromycin): In vitro and in vivo activity of novel lactone-ketolide, against clinically relevant S. pneumoniae (SPN) resistotypes and methicillin-sensitive S. aureus (MSSA) American Society for Microbiology (ASM\/Microbe) No. 456, Boston, MA, USA, (2016)."},{"key":"BFja2016137_CR41","doi-asserted-by":"crossref","unstructured":"Bhatia, A., Chugh, R., Gupta, M. & Iwanowski, P. Nafithromycin single ascending dose (SAD) and food effect (FE) study in healthy subjects American Society for Microbiology (ASM\/Microbe) No. 514, Boston, MA, USA, (2016).","DOI":"10.1093\/ofid\/ofw172.1784"},{"key":"BFja2016137_CR42","unstructured":"Chugh, R., Gupta, M., Iwanowski, P. & Bhatia, A. Nafithromycin phase 1 multiple ascending dose study in healthy subjects. (American Society for Microbiology, (ASM\/Microbe) No. 513, Boston, MA, USA, (2016)."},{"key":"BFja2016137_CR43","doi-asserted-by":"publisher","first-page":"7446","DOI":"10.1021\/jm900729s","volume":"52","author":"TV Magee","year":"2009","unstructured":"Magee, T. V. et al. Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections. J. Med. Chem. 52, 7446\u20137457 (2009).","journal-title":"J. Med. Chem."},{"key":"BFja2016137_CR44","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2174\/1568026033452177","volume":"3","author":"H Takashima","year":"2003","unstructured":"Takashima, H. Structural consideration of macrolide antibiotics in relation to the ribosomal interaction and drug design. Curr. Top. Med. Chem. 3, 991\u2013999 (2003).","journal-title":"Curr. Top. Med. Chem."},{"key":"BFja2016137_CR45","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.chembiol.2010.09.013","volume":"17","author":"H Zhang","year":"2010","unstructured":"Zhang, H., Wang, Y., Wu, J., Skalina, K. & Pfeifer, B. A. Complete biosynthesis of erythromycin A and designed analogs using E. coli as a heterologous host. Chem. Biol. 17, 1232\u20131240 (2010).","journal-title":"Chem. Biol."},{"key":"BFja2016137_CR46","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1021\/ja00401a049","volume":"103","author":"RB Woodward","year":"1981","unstructured":"Woodward, R. B. et al. Asymmetric total synthesis of erythromycin. 1. Synthesis of an erythronolide A secoacid derivative via asymmetric induction. J. Am. Chem. Soc. 103, 3210\u20133213 (1981).","journal-title":"J. Am. Chem. Soc."},{"key":"BFja2016137_CR47","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1021\/ja00401a050","volume":"103","author":"RB Woodward","year":"1981","unstructured":"Woodward, R. B. et al. Asymmetric total synthesis of erythromycin. 2. Synthesis of an erythronolide A lactone system. J. Am. Chem. Soc. 103, 3213\u20133215 (1981).","journal-title":"J. Am. Chem. Soc."},{"key":"BFja2016137_CR48","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1021\/ja00401a051","volume":"103","author":"RB Woodward","year":"1981","unstructured":"Woodward, R. B. et al. Asymmetric total synthesis of erythromycin. 3. Total synthesis of erythromycin. J. Am. Chem. Soc. 103, 3215\u20133217 (1981).","journal-title":"J. Am. Chem. Soc."},{"key":"BFja2016137_CR49","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1021\/cr0301402","volume":"106","author":"A Parenty","year":"2006","unstructured":"Parenty, A., Moreau, X. & Campagne, J. M. Macrolactonizations in the total synthesis of natural products. Chem. Rev. 106, 911\u2013939 (2006).","journal-title":"Chem. Rev."},{"key":"BFja2016137_CR50","doi-asserted-by":"publisher","first-page":"5709","DOI":"10.1016\/j.tet.2007.02.044","volume":"63","author":"P Breton","year":"2007","unstructured":"Breton, P. et al. Total synthesis of erythromycin B. Tetrahedron 63, 5709\u20135729 (2007).","journal-title":"Tetrahedron"},{"key":"BFja2016137_CR51","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.3201\/eid2209.152058","volume":"22","author":"K Poramathikul","year":"2016","unstructured":"Poramathikul, K. et al. Multidrug-resistant Shigella infections in patients with diarrhea, Cambodia, 2014\u20132015. Emerg. Infect. Dis. 22, 1640\u20131643 (2016).","journal-title":"Emerg. Infect. Dis."},{"issue":"Suppl 4","key":"BFja2016137_CR52","doi-asserted-by":"publisher","first-page":"S235","DOI":"10.1093\/cid\/civ709","volume":"61","author":"JA Crump","year":"2015","unstructured":"Crump, J. A. & Heyderman, R. S. A perspective on invasive Salmonella disease in Africa. Clin. Infect. Dis. 61 (Suppl 4), S235\u2013S240 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"BFja2016137_CR53","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/bph.12187","volume":"169","author":"Y Kobayashi","year":"2013","unstructured":"Kobayashi, Y. et al. A novel macrolide\/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. Br. J. Pharmacol. 169, 1024\u20131034 (2013).","journal-title":"Br. J. Pharmacol."},{"key":"BFja2016137_CR54","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.bcp.2007.11.004","volume":"75","author":"A Mitselos","year":"2008","unstructured":"Mitselos, A., Vanden Berghe, P., Peeters, T. L. & Depoortere, I. Differences in motilin receptor desensitization after stimulation with motilin or motilides are due to alternative receptor trafficking. Biochem. Pharmacol. 75, 1115\u20131128 (2008).","journal-title":"Biochem. Pharmacol."},{"issue":"6 Pt 1","key":"BFja2016137_CR55","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1164\/ajrccm.157.6.9710075","volume":"157","author":"S Kudoh","year":"1998","unstructured":"Kudoh, S., Azuma, A., Yamamoto, M., Izumi, T. & Ando, M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am. J. Respir. Crit. Care Med. 157 (6 Pt 1), 1829\u20131832 (1998).","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ja2016137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ja2016137","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/ja.2016.137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/ja2016137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:23:11Z","timestamp":1684430591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ja2016137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,30]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["BFja2016137"],"URL":"https:\/\/doi.org\/10.1038\/ja.2016.137","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,30]]},"assertion":[{"value":"4 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}